期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 31, 期 2, 页码 117-125出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2018.04.002
关键词
Adoptive cell therapy; Chimeric antigen receptor; Engineering; Cancer immunotherapy
类别
资金
- MRC
- Breast Cancer Now
- Cancer Research UK Biotherapeutics Drug Discovery Project Award [C11499/A21623]
- British Lung Foundation
- Experimental Cancer Medicine Centre at King's College London
- King's Health Partners/King's College London Cancer Research UK Cancer Centre
- National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London [IS-BRC-1215-20006]
- MRC [MR/M024733/1, MR/R001936/1] Funding Source: UKRI
Following the landmark approvals by the United States Food and Drug Administration, the adoptive transfer of CD19-directed chimeric antigen receptor (CAR) T-cells has now entered mainstream clinical practice for patients with chemotherapy-resistant or refractory B-cell malignancies. These approvals have followed on from a prolonged period of pre-clinical evaluation, informing the design of clinical trials that have demonstrated unprecedented efficacy in this difficult to treat patient population. However, the delivery of autologous CAR-engineered T-cell therapy is complex, costly and not without significant risk. Here we summarize the key themes of CAR T-cell preclinical development and highlight a number of innovative strategies designed to further address toxicity and improve efficacy. In concert with the emerging promise of precision genome editing, it is hoped these next generation products will increase the repertoire of clinical applications of CAR T-cell therapy in malignant and perhaps other disease settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据